生物活性
VE-822 (Berzosertib) 是选择性ATR抑制剂,Ki< 0.2 nM,ATR选择性比高相关性的PI3K关联酶ATM/DNA-PK高了170倍。作为对XRT和gemcitabine的响应,VE-822(80 nM)减弱ATR信号传导途径,并降低肿瘤细胞存活率。在正常细胞中,VE-822(80 nM)减弱ATR信号通路强度,但并没有增强辐射和gemcitabine杀伤正常细胞的能力。与XRT中的MiaPaCa-2和PSN-1细胞相比,VE-822(80 nM)增加XRT引起的残余γH2AX和53BP1灶。
使用AbMole产品发表的文献
产品使用成果展示
|
数据来源 |
Cancer Res (2017). Figure 7. VE-822 (Abmole Bioscience) |
方法 |
Colony formation assay |
细胞系/动物模型 |
AKC cell lines |
浓度 |
1 μM |
处理时间 |
24 h |
实验结果 |
We next assessed the therapeutic efficacy of an ATR inhibitor (VE-822) with or without gemcitabine in a subcutaneous transplantation model. Intriguingly, while ATR inhibition significantly reduced tumor progression from AKC lines, it had negligible effects on KC tumors. |
|
数据来源 |
Sci Rep (2017). Figure 6. VE-822 (Abmole Bioscience) |
方法 |
oral |
细胞系/动物模型 |
Xenograft mouse model |
浓度 |
30 mg/kg |
处理时间 |
1–3 day |
实验结果 |
While vehicle-treated xenograft tumors derived from H-82 (Fig. 6D), H-526 (Fig. 6E) and H-69 (Fig. 6F) cells displayed a rapid growth, both VE-822 and PF-477736 treatment led to a massively delayed tumor growth in all three models, which was mimicked by a substantial reduction in Ki67 staining on histological examination in tumors that were excised following completion of treatment (Fig. 6G,H). |
|
数据来源 |
Sci Rep (2017). Figure 4. VE-822 (Abmole Bioscience) |
方法 |
oral |
细胞系/动物模型 |
Xenograft mouse model |
浓度 |
30 mg/kg |
处理时间 |
1–3 day |
实验结果 |
Contrary to these substantial therapeutic effects inflicted by VE-822 and PF-477736 in SCLC-bearing animals, we only observed a minute survival extension in VE-822- and PF-477736-treated NSCLC-bearing mice. |
|
数据来源 |
Sci Rep (2017). Figure 3. VE-822 (Abmole Bioscience) |
方法 |
Immunofluorescence |
细胞系/动物模型 |
SCLC and NSCLC cells |
浓度 |
0.75 μM |
处理时间 |
48 h |
实验结果 |
Fully in line with our immunofluorescence data, SCLC cell lines displayed a significantly stronger γH2AX signal following VE-822 and PF-477736 treatment, than their NSCLC counterparts |
|
数据来源 |
Sci Rep (2017). Figure 2. VE-822 (Abmole Bioscience) |
方法 |
Flow cytometry |
细胞系/动物模型 |
SCLC and NSCLC cell |
浓度 |
0.1 μM, 0.75 μM, 3.0 μM |
处理时间 |
48 h |
实验结果 |
Of note, the slow growing cell line RP2 was less sensitive to VE-822 and PF-477736, compared to cell lines RP1, 3 and 4. The rapidly proliferating SCLC cell line RP5 displayed the most pronounced sensitivity to the cell cycle checkpoint abrogating agents VE-822 and PF-477736. |
|
数据来源 |
Cancer Res (2017). VE-822, Figure 7. (AbMole BioScience) |
方法 |
|
细胞系/动物模型 |
KP-, KPAfl/Δ- and KPAΔ/Δ cells |
浓度 |
0.1μM |
处理时间 |
|
实验结果 |
As shown in Figure 7A-C, VE-822 treatment (30mg/kg, orally, days 1-3, 8-10, 15-17) of KP- and KPAfl/Δ-tumor bearing mice did not result in any significant tumor volume changes, compared to vehicle-treated controls. |
|
数据来源 |
Cancer Res (2017). VE-822, Figure 5. (AbMole BioScience) |
方法 |
|
细胞系/动物模型 |
KP-, KPAfl/Δ- and KPAΔ/Δ cells |
浓度 |
0.1μM |
处理时间 |
72 h |
实验结果 |
VE-822 exposure led to a substantial and significant reduction in surviving KPAΔ/Δ colonies, compared to vehicle controls (p < 0.0001) (Fig. 5E, F). Of note, the cytotoxic effect of VE-822 was significantly more pronounced in KPAΔ/Δ cells, compared to KP- and KPAfl/Δcells (p < 0.0001 and p < 0.0001, respectively) (Fig. 5D). VE-822 was genotoxic in all three genotypes and induced maximal damage at 24 hours following drug exposure (Fig. 5I, J, S8B). |
实验参考
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
体内实验* |
动物模型 |
mice bearing PSN-1 or MiaPaCa-2 tumors |
配制 |
saline |
剂量 |
60 mg/kg |
给药处理 |
Oral gavage |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
化学性质
分子量 |
463.55 |
分子式 |
C24H25N5O3S |
CAS号 |
1232416-25-9
|
溶解性(25°C) |
DMSO 24 mg/mL |
储存条件 |
粉末型式 -20°C 3年;4°C 2年
溶于溶剂 -80°C 6个月;-20°C 1个月
|
运输方式 |
冰袋运输,根据产品的不同,可能会有相应调整。 |
储备液配制
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
2.1573 mL |
10.7863 mL |
21.5726 mL |
5 mM |
0.4315 mL |
2.1573 mL |
4.3145 mL |
10 mM |
0.2157 mL |
1.0786 mL |
2.1573 mL |
不同实验动物依据体表面积的等效剂量转换表(参考来源于公开文献)
|
小鼠 |
大鼠 |
兔 |
豚鼠 |
仓鼠 |
狗 |
重量 (kg) |
0.02 |
0.15 |
1.8 |
0.4 |
0.08 |
10 |
体表面积 (m2) |
0.007 |
0.025 |
0.15 |
0.05 |
0.02 |
0.5 |
Km 系数 |
3 |
6 |
12 |
8 |
5 |
20 |
动物 A (mg/kg) = 动物 B (mg/kg) × |
动物 B的Km系数
|
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
参考文献
[1] Qikun Yin, et al. VE-822, a novel DNA Holliday junction stabilizer, inhibits homologous recombination repair and triggers DNA damage response in osteogenic sarcomas
[2] Fubiao Ni, et al. Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system
[3] Helen H N Yan, et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening
[4] Emilio Lecona, et al. Targeting ATR in cancer